Evidence-informed medical pharmacology article updated 10 November 2026. For education; prescribing requires current local labeling and individual patient assessment.
Overview
Fenofibrate is a fibrate lipid-modifying medicine used principally to lower elevated triglycerides. Its triglyceride-lowering effect does not mean it reliably adds cardiovascular event reduction when prescribed to every statin-treated patient. Treat secondary causes, dietary factors, alcohol exposure and cardiovascular risk alongside medications [1–3].
Molecular mechanism
Fenofibrate is hydrolyzed to active fenofibric acid, which activates nuclear peroxisome proliferator-activated receptor alpha (PPAR-α). PPAR-α–RXR heterodimers regulate gene transcription affecting fatty acid oxidation, lipoprotein lipase activity and apolipoprotein C-III. The resulting enhanced catabolism of triglyceride-rich particles reduces serum triglycerides; LDL-C response may vary and can increase in certain severe hypertriglyceridemia phenotypes [1].
Clinical indications and evidence
Severe hypertriglyceridemia, commonly triglycerides ≥500 mg/dL, merits assessment for pancreatitis risk and may require triglyceride-lowering treatment; at ≥1000 mg/dL, urgent dietary and metabolic measures become especially important. Fibrates are used selectively, not automatically for every patient with diabetes and mildly elevated triglycerides. In the PROMINENT outcome trial, the selective PPAR-α modulator pemafibrate lowered triglycerides but did not reduce major cardiovascular events in the studied statin-treated type 2 diabetes population; one should not extrapolate triglyceride reduction into guaranteed cardiovascular benefit [2,3].
Pharmacokinetics and renal function
Fenofibrate formulations differ in absorption and food requirements; the active fenofibric acid is highly protein bound and mainly excreted in urine. Renal impairment increases exposure and requires product-specific dose reduction, and severe renal impairment/dialysis is a contraindication for various labels. Assess baseline and follow-up kidney function; a reversible serum creatinine rise can occur, although not every rise represents permanent nephron damage [1,2].
Adverse effects and contraindications
Myalgia, myopathy or rhabdomyolysis can occur, especially with statins, older age, renal impairment or hypothyroidism. Fenofibrate may cause hepatotoxicity, gallstones and gastrointestinal adverse effects. Active liver disease and preexisting gallbladder disease are important contraindications in US labels; monitor liver enzymes and symptoms. Fenofibrate is not interchangeable with gemfibrozil: gemfibrozil has substantially greater interaction concern with some statins [1,2].
Interactions and monitoring
Fenofibrate may potentiate warfarin anticoagulation, requiring INR reassessment during initiation or discontinuation. Combination with a statin should follow a clear indication and careful muscle/renal assessment. Repeat lipid testing to establish response; discontinue ineffective therapy or revise treatment if the expected triglyceride reduction is not achieved [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. LIPOFEN (fenofibrate) prescribing information. 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021612s026lbl.pdf
- Blumenthal RS, et al. 2026 ACC/AHA multisociety guideline on management of dyslipidemia. Circulation. 2026;153:e1154–e1276. Available from: https://doi.org/10.1161/CIR.0000000000001423
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.